Prof. Xuguang Li

University of Ottawa, Canada

Scientist/Professor

Email: Sean_Li@hc-sc.gc.ca, sean.li8888@gmail.com

Qualifications

Ph.D., McGill University, Canada

M.Sc., National Vaccine and Serum Institute, China

M.D., Medical College of Suzhou University, China

Publications(selected)

1. Doyle TD, AM Hashem, C. Li, G Van Domselaar, L Larocque, J. Wang, D Smith. T Cyr, A Farnsworth, R. He, AC Hurt, EG Brown, X. Li.  2013. Universal Anti-Neuraminidase AntibodyInhibiting all Influenza A Subtypes.Antiviral Res. 100(2):567-74(*Selected as highlighted article).
   
2. She YM, K Cheng, A Farnsworth, X. Li, TD Cyr. 2013. Surface Modifications of Influenza Proteins Upon Virus Inactivation by Beta-Propiolactone.  Proteomics  13(23-24):3537-47.
3. Doyle TM., B. Jaentschke, G. Van Domselaar, A Hashem, A. Farnsworth, N. Forbes, C. Li., J. Wang., R. He, EG Brown, X. Li. 2013. The universal epitope of influenza A viral neuraminidasefundamentally contributes to enzyme activity and viral replication.  J. Biol. Chem. 288(25):18283-9.
4. Hashem A, C Gravel, A. Farnsworth, W. Zou, M Lemieux, K Xu, C. Li, J. Wang, M.F. Goneau, M. Merziotis, R  He,  M. Gilbert, X. Li. 2013. A novel synthetic receptor-based immunoassay forinfluenza vaccinequantification. PloS One;8(2):e55428. doi: 10.1371/journal.pone.0055428.
5. Elmgren L, X. Li, C. Wilson, R. Ball, J. Wang, K. Cichutek, M. Pfleiderer, A. Kato, M. Cavaleri, J. Southern, T. Jivapaisarnpong, P. Minor,  E. Griffiths, Y. Sohn, David Wood, 2012. A GlobalRegulatory Science Agenda for Vaccines. Vaccine. 2013 Apr 18;31 Suppl 2:B163-75.
6. Yu L, C. Rao, X. Shi, Y Li, K. Gao, X. Li, J. Wang. 2012. A novel bioassay for the activity determination of therapeutic human brain natriuretic peptide (BNP). PloS One. 7(11):e49934. doi:10.1371/journal.pone.0049934.
7. Doyle T, X Li, 2012. Alternative roles of neuraminidase in influenza A viral propagation.  J. Virol. Antiviral Res. 2012, 1:1    doi: 10.4172/jva.1000e104.
8. Bliu A, M Lemieux, C. Li, X. Li, J. Wang and A. Farnsworth. 2012 Modifying the thermostability of inactivated influenza vaccines. Vaccine. 30(37):5506-11.
9. Creskey MC, C Li, J Wang, M Girard, A Farnsworth, X.Li, DG Smith, TD Cyr. 2012. Simultaneous quantification of the viral hemagglutinin and neuraminidase in influenza vaccine by LC-MSE.Vaccine 30(32):4762-70.
10. Hong A, D Han, CJ Wright, T Burch, J Piper, C Osiowy, C Gao, K Dick, TF Booth, X. Li,  R He 2012. The Interaction between Hepatitis B Virus X Protein and AIB1 Oncogene is Required forthe Activation of NF B Signal Transduction. Biochem Biophys Res Comm. 423(1):6-12.
11. Hashem AM, B. Jaentschke,  C. Gravel,  M Tocchi, TM Doyle, M Rosu-Myles, R He, X. Li. 2012 Subcutaneous immunization with recombinant adenovirus expressing influenza Aprotects mice against lethal viral challenge. Hum Vaccin Immunother. 8(4): 1-4.
12. Russell M, C. Li,,  L. Larocque, A. Farnsworth, J. Wang, R He, X. Li.  2011  Rapid and Accurate Determination of the Potency of Varicella Vaccine by Quantitative Polymerase ChainReaction. Vaccine 2011 Nov 3; 29(47):8490-5.
13. Hashem AM, TM Doyle, G Van Domselaar, A Farnsworth, C Li, J Wang, R He, X. Li. 2011, Recent Developments in Bioinformatics Analyses of Influenza A Virus Surface Glycoproteins andtheir Biological Relevance. Current Bioinformatics 6(4): 415 -426.
14. Flaman AS, C Gravel, A.M. Hashem,  M Tocchi,  X. Li. 2011 The effect of interferon-  on the expression of cytochrome P450 3A4 in human hepatoma cells. Toxicol Appl Pharmacol.253:130–136.
15. Johnston MJ, Frahm G, X. Li, Durocher Y, Hefford MA. 2011. O-linked glycosylation leads to decreased thermal stability of interferon alpha 2b as measured by two orthogonal techniques.Pharmaceutical Research. 28(7):1661-1667.
16. Lorbetskie B, J. Wang, C. Gravel, C. Allen, M. Walsh, A.Rinfret, X. Li, and M Girard. 2011. Quantitative Analysis of Hemagglutinin in Influenza Vaccine Preparations by Reversed-PhaseHPLC on Non-Porous Silica: Optimization, Qualification, Comparative Evaluation with Western Blot and Single Radial Immunodiffusion Assays and Applicability during the 2009 H1N1InfluenzaPandemic. Vaccine 29(18):3377-89.
    
17. Larocque L, A. Bliu, R. Xu, A Diress, J Wang, R. Lin, R. He, M. Girard, X. Li . 2011. Bioactivity determination of native and variant forms of therapeutic interferons. J. Biomed. Biotechnol.2011;2011:174615.
18. Farnsworth A., T.D. Cyr, C. Li, J. Wang, and X. Li. 2011. Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain. Vaccine 29(8):1529-33.
19. Gravel C, C Li, J Wang, B Jaentschke, G Van Domselaar, R He, X. Li. 2011.  Quantitative Analyses of all Influenza Type A Viral Hemagglutinins and Neuraminidases using UniversalAntibodies in simple Slot Blot Assays. J. Vis. Exp. 2011 Apr 4;(50). pii: 2784. doi: 10.3791/2784.
20. Hashem A, G. Van Domselaar, C. Li, J. Wang, Y-M She, T.D. Cyr, J. Sui, R. He, W.A. Marasco, X. Li. 2010.Universal Antibodies against the Highly Conserved Influenza Fusion PeptideCross-Neutralize Several Subtypes of Influenza A Virus. Biochem Biophys Res Comm. 403: 247–251.

Profile Details

http://www.med.uottawa.ca/bmi/eng/LI-sean.html